RU2018131519A - Стромальные стволовые клетки жировой ткани для использования в лечении рефракторных сложных перианальных фистул при болезни крона - Google Patents
Стромальные стволовые клетки жировой ткани для использования в лечении рефракторных сложных перианальных фистул при болезни крона Download PDFInfo
- Publication number
- RU2018131519A RU2018131519A RU2018131519A RU2018131519A RU2018131519A RU 2018131519 A RU2018131519 A RU 2018131519A RU 2018131519 A RU2018131519 A RU 2018131519A RU 2018131519 A RU2018131519 A RU 2018131519A RU 2018131519 A RU2018131519 A RU 2018131519A
- Authority
- RU
- Russia
- Prior art keywords
- use according
- fistula
- weeks
- preceding paragraphs
- stem cells
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title claims 3
- 206010002156 anal fistula Diseases 0.000 title claims 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 206010016717 Fistula Diseases 0.000 claims 6
- 230000003890 fistula Effects 0.000 claims 6
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- -1 CD11c Proteins 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 102100022464 5'-nucleotidase Human genes 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 102100022002 CD59 glycoprotein Human genes 0.000 claims 1
- 102100037241 Endoglin Human genes 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims 1
- 102100022338 Integrin alpha-M Human genes 0.000 claims 1
- 102100022297 Integrin alpha-X Human genes 0.000 claims 1
- 102100025304 Integrin beta-1 Human genes 0.000 claims 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000002650 immunosuppressive therapy Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0653—Adipocytes; Adipose tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (13)
1. Применение аллогенных стромальных стволовых клеток жировой ткани для лечения многопроходной рефракторной сложной перианальной фистулы у пациента с болезнью Крона, где дозу примерно 120 милион клеток водят за одну процедуру, где кадый проход полчучает фистулы получает часть этой дозы, и где примерно половины дозы вводят в ткань, окружающую окружающую внутреннее отверстие или отверстия, а другую половину вводят в стенки фистул по всем проходам.
2. Применение по п. 1, где фистула содержит два внутриенних отверстия.
3. Применение по пп.1 или 2, где фистула содержит два или три внешних отсерстий.
4. Применение по любому из предедыдущих пунктов, где фистула является рефракторной к одному или нескольким из (i) антибиотика, (ii) иммуносупрессанта и (iii) анти-TNF терапии.
5. Применение по любому из предедыдущих пунктов, где где пациент не получает никакой или обе из анти-TNF терапии и иммуносупрессорной терапии.
6. Применение по любому из предедыдущих пунктов, где пациент:
(a) имеет неактивную или слабоактивную болезнь Крона; и/или
(b) люминальную болезнь Крона.
7. Применение по любому из предедыдущих пунктов, где где терапия индуцирует комбинированную ремиссию или клиническую ремиссию.
8. Применение по п. 7, где где комбинированная ремиссия или клиническая ремиссия достигается за 24 недели, за 18 недель или за 12 недель.
9. Применение по п 8, где где комбинированная ремиссия или клиническая ремиссия достигается за 8 недель или за 6 недель.
10. Применение по любому из предедыдущих пунктов, где где фистулу контролируют при помощи МРТ.
11. Применение по любому из предедыдущих пунктов, где размноженные аллогенные стромальные стволовые клетки жировой ткани экспрессируют четыре или более HLAI, CD29, CD44, CD59, CD73, CD90 и CD105; и не экспрессируют четыре или более HLAII, CD11b, CD11c, CD14, CD45, CD31, CD34 и CD80.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1604304.4 | 2016-03-14 | ||
| GBGB1604304.4A GB201604304D0 (en) | 2016-03-14 | 2016-03-14 | Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease |
| PCT/IB2017/051468 WO2017158509A1 (en) | 2016-03-14 | 2017-03-14 | Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018131519A true RU2018131519A (ru) | 2020-04-15 |
| RU2018131519A3 RU2018131519A3 (ru) | 2020-07-10 |
| RU2742308C2 RU2742308C2 (ru) | 2021-02-04 |
Family
ID=55952284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018131519A RU2742308C2 (ru) | 2016-03-14 | 2017-03-14 | Стромальные стволовые клетки жировой ткани для использования в лечении рефракторных сложных перианальных фистул при болезни крона |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10357518B2 (ru) |
| EP (2) | EP4074322A1 (ru) |
| JP (2) | JP6931656B2 (ru) |
| KR (1) | KR102277789B1 (ru) |
| CN (2) | CN108883135B (ru) |
| AU (1) | AU2017232718B2 (ru) |
| BE (1) | BE1024781B1 (ru) |
| CA (1) | CA3017694C (ru) |
| DE (1) | DE102017002458B4 (ru) |
| DK (1) | DK3219321T3 (ru) |
| ES (2) | ES2911718T3 (ru) |
| FR (1) | FR3048614B1 (ru) |
| GB (2) | GB201604304D0 (ru) |
| HR (1) | HRP20220539T1 (ru) |
| HU (1) | HUE058739T2 (ru) |
| IL (2) | IL261730B2 (ru) |
| LT (1) | LT3219321T (ru) |
| MX (1) | MX2018010699A (ru) |
| NL (1) | NL2018512B1 (ru) |
| NO (1) | NO345415B1 (ru) |
| PL (1) | PL3219321T3 (ru) |
| RS (1) | RS63163B1 (ru) |
| RU (1) | RU2742308C2 (ru) |
| SG (2) | SG10202008992YA (ru) |
| SI (1) | SI3219321T1 (ru) |
| WO (1) | WO2017158509A1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060045872A1 (en) | 2004-08-25 | 2006-03-02 | Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco | Use of adipose tissue-derived stromal stem cells in treating fistula |
| GB201604304D0 (en) * | 2016-03-14 | 2016-04-27 | Tigenix S A U | Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease |
| AU2018244922A1 (en) | 2017-03-30 | 2019-09-12 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with live biotherapeutics |
| WO2020174002A1 (en) * | 2019-02-27 | 2020-09-03 | Tigenix, S.A.U. | Improved stem cell populations for allogeneic therapy |
| CN111481573A (zh) * | 2020-03-26 | 2020-08-04 | 卡替（上海）生物技术股份有限公司 | 牙髓间充质干细胞在制备克罗恩病治疗药物中的用途 |
| AU2021388154A1 (en) * | 2020-11-25 | 2023-06-22 | Flagship Pioneering, Inc. | Adipogenic cell compositions and methods |
| WO2023230524A1 (en) * | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vi, Llc | Compositions of secretory and/or catalytic cells and methods using the same |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US6010696A (en) | 1990-11-16 | 2000-01-04 | Osiris Therapeutics, Inc. | Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells |
| US5733542A (en) | 1990-11-16 | 1998-03-31 | Haynesworth; Stephen E. | Enhancing bone marrow engraftment using MSCS |
| JPH09502421A (ja) | 1992-12-02 | 1997-03-11 | シエル・インターナシヨナル・リサーチ・マートシヤツピイ・ベー・ブイ | アゾキシシアノベンゼン誘導体 |
| US5578475A (en) | 1993-07-12 | 1996-11-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
| US5472183A (en) | 1994-03-17 | 1995-12-05 | Nisca Corporation | Sheet feeding device with multiple sheet stackers |
| AU686823B2 (en) | 1994-06-06 | 1998-02-12 | Case Western Reserve University | Biomatrix for tissue regeneration |
| US6174333B1 (en) | 1994-06-06 | 2001-01-16 | Osiris Therapeutics, Inc. | Biomatrix for soft tissue regeneration using mesenchymal stem cells |
| IL122290A0 (en) | 1995-06-07 | 1998-04-05 | Inex Pharmaceuticals Corp | Lipid-nucleic acid complex its preparation and use |
| US6051429A (en) | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| US6546106B2 (en) | 1996-09-03 | 2003-04-08 | New Transducers Limited | Acoustic device |
| US5705308A (en) | 1996-09-30 | 1998-01-06 | Eastman Kodak Company | Infrared-sensitive, negative-working diazonaphthoquinone imaging composition and element |
| AU1615599A (en) | 1997-12-02 | 1999-06-16 | Zen Bio, Inc. | Differentiation of adipose stromal cells into osteoblasts and uses thereof |
| US6368636B1 (en) | 1998-03-18 | 2002-04-09 | Osiris Therapeutics, Inc. | Mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| US9585916B2 (en) | 1999-03-26 | 2017-03-07 | Northern Therapeutics Inc. | Cell based therapy for the pulmonary system |
| JP2002510655A (ja) | 1998-04-03 | 2002-04-09 | オシリス セラピューティクス，インコーポレイテッド | 免疫抑制剤としての間葉幹細胞によるｔ細胞応答を阻害する方法とその利用 |
| US6546105B1 (en) | 1998-10-30 | 2003-04-08 | Matsushita Electric Industrial Co., Ltd. | Sound image localization device and sound image localization method |
| US6777231B1 (en) | 1999-03-10 | 2004-08-17 | The Regents Of The University Of California | Adipose-derived stem cells and lattices |
| US20030082152A1 (en) | 1999-03-10 | 2003-05-01 | Hedrick Marc H. | Adipose-derived stem cells and lattices |
| US20050153442A1 (en) | 1999-03-10 | 2005-07-14 | Adam Katz | Adipose-derived stem cells and lattices |
| CN1352696A (zh) | 1999-03-10 | 2002-06-05 | 匹兹堡大学联邦制高等教育 | 脂肪来源的干细胞和网格 |
| US7670628B2 (en) | 1999-07-07 | 2010-03-02 | Angioblast Systems, Inc. | Mesenchymal precursor cell |
| US6555374B1 (en) | 1999-08-19 | 2003-04-29 | Artecel Sciences, Inc. | Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof |
| US20020155096A1 (en) | 2001-02-23 | 2002-10-24 | Chancellor Michael B. | Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair |
| US20030054331A1 (en) | 2001-09-14 | 2003-03-20 | Stemsource, Inc. | Preservation of non embryonic cells from non hematopoietic tissues |
| AU2002359390A1 (en) * | 2001-11-09 | 2003-05-19 | Artecel Sciences, Inc. | Endocrine pancreas differentiation of adipose tissue-derived stromal cells and uses thereof |
| CA2466880A1 (en) | 2001-11-09 | 2003-05-15 | Artecel Sciences, Inc. | Methods and compositions for the use of stromal cells to support embryonic and adult stem cells |
| US7771716B2 (en) | 2001-12-07 | 2010-08-10 | Cytori Therapeutics, Inc. | Methods of using regenerative cells in the treatment of musculoskeletal disorders |
| WO2003077865A2 (en) | 2002-03-15 | 2003-09-25 | Baxter International Inc. | Methods and compositions for directing cells to target organs |
| US7749710B2 (en) | 2002-06-14 | 2010-07-06 | Xintela Ab | Marker for stem cells and its use |
| US20040101959A1 (en) | 2002-11-21 | 2004-05-27 | Olga Marko | Treatment of tissue with undifferentiated mesenchymal cells |
| ATE482725T1 (de) | 2003-04-01 | 2010-10-15 | Us Dept Of Veteran S Affaires | Auf stammzellen, vorläuferzellen oder targetzellen basierende behandlung von multiorganversagen. |
| ES2265199B1 (es) | 2003-06-12 | 2008-02-01 | Cellerix, S.L. | Celulas madre adultas multipotentes procedentes de condrocitos desdiferenciados y sus aplicaciones. |
| ES2600555T3 (es) | 2003-06-27 | 2017-02-09 | DePuy Synthes Products, Inc. | Reparación y regeneración de tejido ocular usando células derivadas del post parto |
| US7645229B2 (en) | 2003-09-26 | 2010-01-12 | Armstrong David N | Instrument and method for endoscopic visualization and treatment of anorectal fistula |
| JP4749331B2 (ja) | 2003-10-07 | 2011-08-17 | 株式会社バイオマスター | 脂肪由来前駆細胞の細胞分化 |
| KR100821128B1 (ko) | 2003-11-04 | 2008-04-14 | 가부시키가이샤 바이오마스타 | 지방 조직으로부터 줄기세포를 생성하는 방법 및 시스템 |
| JP2007530543A (ja) | 2004-03-22 | 2007-11-01 | オシリス セラピューティクス，インコーポレイテッド | 間葉幹細胞及びその使用法 |
| US20080095749A1 (en) | 2004-03-22 | 2008-04-24 | Sudeepta Aggarwal | Mesenchymal stem cells and uses therefor |
| RU2252252C1 (ru) | 2004-04-09 | 2005-05-20 | Тепляшин Александр Сергеевич | Способ выделения мезенхимальных стволовых клеток |
| ES2313805B1 (es) | 2004-10-04 | 2009-12-23 | Cellerix, S.L. | Identificacion y aislamiento de celulas multipotentes de tejido mesenquimal no osteocondral. |
| US20060045872A1 (en) | 2004-08-25 | 2006-03-02 | Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco | Use of adipose tissue-derived stromal stem cells in treating fistula |
| ES2264862B8 (es) | 2004-08-25 | 2017-01-20 | Cellerix, S.L. | Biomaterial para sutura. |
| WO2006029347A2 (en) | 2004-09-03 | 2006-03-16 | University Of Maryland, Baltimore | Integrin cd18 is a novel stromal stem cell marker and functions to promote osteogenesis |
| WO2006110582A1 (en) | 2005-04-08 | 2006-10-19 | Xcyte Therapies, Inc. | Compositions and methods for the treatment of burns and sepsis |
| KR20080048555A (ko) | 2005-09-23 | 2008-06-02 | 셀레릭스, 에스.엘. | 면역조절활성을 갖는 세포 개체군, 분리 방법 및 용도 |
| EP1795588A1 (en) | 2005-12-07 | 2007-06-13 | Cellerix, S.L. | Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease |
| US20120269774A1 (en) | 2006-09-21 | 2012-10-25 | Medistem Laboratories, Inc | Allogeneic stem cell transplants in non-conditioned recipients |
| US20110262402A1 (en) | 2007-09-07 | 2011-10-27 | Masahiko Kuroda | Therapeutic and prophylactic agents for arthritis |
| KR20140107677A (ko) | 2007-09-19 | 2014-09-04 | 플루리스템 리미티드 | 지방 또는 태반 조직 유래의 부착 세포 및 이의 치료 용도 |
| ES2595103T3 (es) | 2007-10-17 | 2016-12-27 | Txcell | Células Tr1, células madre mesenquimales y usos de estas |
| GB0814249D0 (en) | 2008-08-04 | 2008-09-10 | Cellerix Sa | Uses of mesenchymal stem cells |
| ES2345867B1 (es) * | 2009-04-03 | 2011-07-28 | Fundacion Instituto Mediterraneo Para La Biotecnologia Y La Investigacion Sanitaria (Imabis) | Celulas madre multipotentes derivadas de estroma de mesenterio. |
| KR101328604B1 (ko) * | 2009-04-28 | 2013-11-11 | (주)안트로젠 | 누공 치료를 위한 자가 및 동종의 지방 유래 스트로마 줄기세포 조성물 |
| AU2010269962B2 (en) | 2009-07-09 | 2016-04-14 | Takeda Pharmaceutical Company Limited | Methods and compositions for use in cellular therapies |
| SG190412A1 (en) * | 2010-12-06 | 2013-06-28 | Quark Pharmaceuticals Inc | Double stranded oligonucleotide compounds comprising threose modifications |
| JP6018081B2 (ja) | 2011-01-12 | 2016-11-02 | ティジェニクス エス．エー．ユー． | 自己免疫および炎症性疾患におけるリンパ系内投与用の脂肪由来間葉系幹細胞 |
| JP2014508527A (ja) | 2011-03-11 | 2014-04-10 | ティゲニクス、エセ、ア、ウ | 免疫調節活性を有する細胞集団、単離方法および使用 |
| US20140134140A1 (en) | 2012-11-09 | 2014-05-15 | Case Western Reserve University | Mesenchymal stem cell compositions for the treatment of microbial infections |
| AU2014230014B2 (en) * | 2013-03-15 | 2019-11-14 | Tigenix, S.A.U. | Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(MSC) |
| WO2014207679A1 (en) | 2013-06-25 | 2014-12-31 | Tigenix S.A.U. | Cell populations having immunoregulatory activity, methods for the preparation and uses thereof |
| NZ727950A (en) * | 2014-06-30 | 2022-07-01 | Takeda Pharmaceuticals Co | Mesenchymal stromal cells for treating sepsis |
| WO2017051421A1 (en) * | 2015-09-24 | 2017-03-30 | Cellect Biotherapeutics Ltd. | Methods for propagating mesenchymal stem cells (msc) for use in transplantation |
| GB201604304D0 (en) * | 2016-03-14 | 2016-04-27 | Tigenix S A U | Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease |
-
2016
- 2016-03-14 GB GBGB1604304.4A patent/GB201604304D0/en not_active Ceased
-
2017
- 2017-03-14 CN CN201780017154.3A patent/CN108883135B/zh active Active
- 2017-03-14 IL IL261730A patent/IL261730B2/en unknown
- 2017-03-14 US US15/458,509 patent/US10357518B2/en active Active
- 2017-03-14 EP EP22163484.3A patent/EP4074322A1/en active Pending
- 2017-03-14 SG SG10202008992YA patent/SG10202008992YA/en unknown
- 2017-03-14 EP EP17160932.4A patent/EP3219321B1/en active Active
- 2017-03-14 FR FR1752073A patent/FR3048614B1/fr active Active
- 2017-03-14 IL IL298107A patent/IL298107B2/en unknown
- 2017-03-14 CN CN202211257331.4A patent/CN115569151A/zh active Pending
- 2017-03-14 NL NL2018512A patent/NL2018512B1/nl active
- 2017-03-14 SG SG11201807404XA patent/SG11201807404XA/en unknown
- 2017-03-14 HU HUE17160932A patent/HUE058739T2/hu unknown
- 2017-03-14 JP JP2018548356A patent/JP6931656B2/ja active Active
- 2017-03-14 SI SI201731122T patent/SI3219321T1/sl unknown
- 2017-03-14 PL PL17160932T patent/PL3219321T3/pl unknown
- 2017-03-14 MX MX2018010699A patent/MX2018010699A/es unknown
- 2017-03-14 DK DK17160932.4T patent/DK3219321T3/da active
- 2017-03-14 AU AU2017232718A patent/AU2017232718B2/en active Active
- 2017-03-14 GB GB1704065.0A patent/GB2548490B/en active Active
- 2017-03-14 RU RU2018131519A patent/RU2742308C2/ru active
- 2017-03-14 LT LTEP17160932.4T patent/LT3219321T/lt unknown
- 2017-03-14 ES ES17160932T patent/ES2911718T3/es active Active
- 2017-03-14 KR KR1020187029414A patent/KR102277789B1/ko active IP Right Grant
- 2017-03-14 NO NO20170376A patent/NO345415B1/en unknown
- 2017-03-14 BE BE2017/5156A patent/BE1024781B1/de active IP Right Grant
- 2017-03-14 DE DE102017002458.8A patent/DE102017002458B4/de active Active
- 2017-03-14 WO PCT/IB2017/051468 patent/WO2017158509A1/en active Application Filing
- 2017-03-14 CA CA3017694A patent/CA3017694C/en active Active
- 2017-03-14 ES ES201700204A patent/ES2681774B1/es active Active
- 2017-03-14 RS RS20220355A patent/RS63163B1/sr unknown
- 2017-03-14 HR HRP20220539TT patent/HRP20220539T1/hr unknown
-
2019
- 2019-06-25 US US16/452,321 patent/US11273182B2/en active Active
-
2021
- 2021-05-17 JP JP2021083406A patent/JP2021119789A/ja active Pending
-
2022
- 2022-02-14 US US17/671,479 patent/US20220249574A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018131519A (ru) | Стромальные стволовые клетки жировой ткани для использования в лечении рефракторных сложных перианальных фистул при болезни крона | |
| Tompkins et al. | Preclinical studies of stem cell therapy for heart disease | |
| JP2019508455A5 (ru) | ||
| JP2021119789A5 (ru) | ||
| MX2019010733A (es) | Metodos para tratar la enfermedad de crohn y la colitis ulcerosa. | |
| Lin et al. | Mesenchymal stem cells transplantation suppresses inflammatory responses in global cerebral ischemia: contribution of TNF-α-induced protein 6 | |
| Quijada et al. | Preservation of myocardial structure is enhanced by pim-1 engineering of bone marrow cells | |
| IN2015DN01616A (ru) | ||
| MX2007005200A (es) | Plaquetas a partir de celulas germinales. | |
| Perotti et al. | A concise review on extracorporeal photochemotherapy: Where we began and where we are now and where are we going! | |
| US20200030380A1 (en) | Stimulation of therapeutic angiogenesis by t regulatory cells | |
| NZ608734A (en) | Bone marrow derived cd271 precursor cells for cardiac repair | |
| Matsuda et al. | Human cardiac stem cells with reduced notch signaling show enhanced therapeutic potential in a rat acute infarction model | |
| EP1807509A4 (en) | MULTIPOTENT STEM CELLS ISOLATED FROM UMBILICAL CORD BLOOD AND CELL THERAPEUTIC AGENT CONTAINING THESE CELLS FOR THE TREATMENT OF ISCHEMIC DISEASE | |
| SG11201900986YA (en) | Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells | |
| Chen et al. | Ultrasound-targeted microbubble destruction enhances delayed BMC delivery and attenuates post-infarction cardiac remodelling by inducing engraftment signals | |
| Liu et al. | Mesenchymal stem cells suppress CaN/NFAT expression in the pulmonary arteries of rats with pulmonary hypertension | |
| Nath et al. | Reticulin fibres anchor leukaemic blasts in the marrow of patients with acute lymphoblastic leukaemia | |
| JP2016510808A5 (ru) | ||
| Fan et al. | Human umbilical cord mesenchymal stem cells transplantation improves lower limb ischemia of diabetic rabbits | |
| KR101382566B1 (ko) | 태반 양막 유래 중간엽 줄기세포의 배양방법 및 말초 동맥 질환 치료법 및 조성물 | |
| SG11201900983TA (en) | Amelioration and treatment of chronic lung disease using pluripotent stem cells | |
| Lebow | Case examples: Working with difficult divorce. | |
| Policy | Navbar Search Filter Mobile Enter search term | |
| Shuster-Hyman | Biodistribution and Fate of Intravenously-Delivered First Trimester Human Umbilical Cord Perivascular Cells in a Murine Model of Systemic Inflammation |